302 related articles for article (PubMed ID: 29336190)
21. Aerosol Foam Formulation of Fixed Combination Calcipotriene Plus Betamethasone Dipropionate is Highly Efficacious in Patients With Psoriasis Vulgaris: Pooled Data From Three Randomized Controlled Studies.
Stein Gold L; Lebwohl M; Menter A; Villumsen J; Rosen M; Koo J
J Drugs Dermatol; 2016 Aug; 15(8):951-7. PubMed ID: 27537995
[TBL] [Abstract][Full Text] [Related]
22. Pooled safety analysis of calcipotriol plus betamethasone dipropionate gel for the treatment of psoriasis on the body and scalp.
Kragballe K; van de Kerkhof P
J Eur Acad Dermatol Venereol; 2014 May; 28 Suppl 2():10-21. PubMed ID: 24684739
[TBL] [Abstract][Full Text] [Related]
23. Calcipotriol/betamethasone dipropionate aerosol foam in the treatment of psoriasis: new perspectives for the use of an innovative topical treatment from real-life experience.
Fabbrocini G; Dauden E; Jalili A; Bewley A
G Ital Dermatol Venereol; 2020 Apr; 155(2):212-219. PubMed ID: 32394674
[TBL] [Abstract][Full Text] [Related]
24. Rapid onset of action of calcipotriol/betamethasone dipropionate cutaneous foam in psoriasis, even in patients with more severe disease.
Pink AE; Jalili A; Berg P; Calzavara-Pinton PG; de la Cueva Dobao P; Thaçi D; Torpet M; Jensen KL; Segaert S
J Eur Acad Dermatol Venereol; 2019 Jun; 33(6):1116-1123. PubMed ID: 30916417
[TBL] [Abstract][Full Text] [Related]
25. Vasoconstrictor potency of fixed-dose combination calcipotriol (50 μg/g) and betamethasone dipropionate (0.5 mg/g) cutaneous foam versus other topical corticosteroids used to treat psoriasis vulgaris.
Queille-Roussel C; Nielsen J; Lacour JP
J Dermatolog Treat; 2019 Sep; 30(6):529-533. PubMed ID: 30582717
[No Abstract] [Full Text] [Related]
26. Patients with psoriasis have different preferences for topical therapy, highlighting the importance of individualized treatment approaches: randomized phase IIIb PSO-INSIGHTFUL study.
Hong CH; Papp KA; Lophaven KW; Skallerup P; Philipp S
J Eur Acad Dermatol Venereol; 2017 Nov; 31(11):1876-1883. PubMed ID: 28796913
[TBL] [Abstract][Full Text] [Related]
27. Cost-effectiveness of the two-compound formulation calcipotriol and betamethasone dipropionate compared with commonly used topical treatments in the management of moderately severe plaque psoriasis in Scotland.
Bottomley JM; Auland ME; Morais J; Boyd G; Douglas WS
Curr Med Res Opin; 2007 Aug; 23(8):1887-901. PubMed ID: 17610804
[TBL] [Abstract][Full Text] [Related]
28. Calcipotriol/betamethasone dipropionate aerosol foam for the treatment of psoriasis vulgaris: a review of real-world evidence (RWE).
Gerdes S; Velasco M; Wu JJ; Hubo M; Veverka KA
J Dermatolog Treat; 2021 Dec; 32(8):883-893. PubMed ID: 31986945
[TBL] [Abstract][Full Text] [Related]
29. The Aerosol Foam Formulation of the Fixed Combination Calcipotriene Plus Betamethasone Dipropionate Improves the Health-Related Quality of Life in Patients With Psoriasis Vulgaris: Results from the Randomized PSO-FAST Study.
Leonardi C; Bagel J; Yamauchi P; Pariser D; Xu Z; Moller A; Osterdal ML; Stein Gold L
J Drugs Dermatol; 2016 Aug; 15(8):981-7. PubMed ID: 27537999
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of proactive treatment with twice-weekly topical Cal/BD foam in patients with plaque psoriasis undergoing HPA-axis testing: a PSO-LONG subgroup analysis.
Papp K; Adamski Z; Guenther L; Liljedahl M; Miasik-Pogodzinska A; Szponar-Bojda A; Lynde C; Nutt T; Mørch MH; Tyring S; Werschler W; Reich A; Sadick N; Turchin I; Lacour JP
J Dermatolog Treat; 2022 Jun; 33(4):2297-2304. PubMed ID: 34365872
[TBL] [Abstract][Full Text] [Related]
31. Real-life effectiveness of once-daily calcipotriol and betamethasone dipropionate gel vs. ointment formulations in psoriasis vulgaris: final analysis of the 52-week PRO-long study.
Lambert J; Hol CW; Vink J
J Eur Acad Dermatol Venereol; 2015 Dec; 29(12):2349-55. PubMed ID: 26337069
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and Safety of Calcipotriene 0.005%/Betamethasone Dipropionate 0.064% Foam With Apremilast for Moderate Plaque Psoriasis.
Kircik LH; Schlesinger TE; Tanghetti E
J Drugs Dermatol; 2020 Sep; 19(9):874-880. PubMed ID: 33026749
[TBL] [Abstract][Full Text] [Related]
33. Efficacy, safety, and cost-effectiveness of all-trans retinoic acid/Clobetasol Propionate Compound Ointment in the treatment of mild to moderate psoriasis vulgaris: A randomized, single-blind, multicenter clinical trial.
Xia L; Li R; Wang Y; Lin Z; Zheng J; Li X; Lu Q; Zhang J; Jin H; Fu L; Zhang X; Liu Y; Yang S; Xiao F; Gao XH
Dermatol Ther; 2018 Sep; 31(5):e12632. PubMed ID: 30253049
[TBL] [Abstract][Full Text] [Related]
34. Twice-weekly topical calcipotriene/betamethasone dipropionate foam as proactive management of plaque psoriasis increases time in remission and is well tolerated over 52 weeks (PSO-LONG trial).
Lebwohl M; Kircik L; Lacour JP; Liljedahl M; Lynde C; Mørch MH; Papp KA; Perrot JL; Gold LS; Takhar A; Thaçi D; Warren RB; Wollenberg A
J Am Acad Dermatol; 2021 May; 84(5):1269-1277. PubMed ID: 32950546
[TBL] [Abstract][Full Text] [Related]
35. Matching-adjusted indirect comparison of efficacy outcomes in trials of calcipotriol plus betamethasone dipropionate foam and cream formulations for the treatment of plaque psoriasis.
Papp KA; Thoning H; Gerdes S; Megna M; Brandi H; Jablonski Bernasconi MY; Yélamos O
J Dermatolog Treat; 2022 Nov; 33(7):3005-3013. PubMed ID: 35875991
[TBL] [Abstract][Full Text] [Related]
36. Itch relief in patients with psoriasis: effectiveness of calcipotriol plus betamethasone dipropionate foam.
Jalili A; Lebwohl M; Stein Gold L; Andersen SB; Jensen KL; Pink AE; Segaert S; Berg P; Calzavara-Pinton PG; de la Cueva Dobao P; Thaçi D
J Eur Acad Dermatol Venereol; 2019 Apr; 33(4):709-717. PubMed ID: 30520168
[TBL] [Abstract][Full Text] [Related]
37. Budget impact model in moderate-to-severe psoriasis vulgaris assessing effects of calcipotriene and betamethasone dipropionate foam on per-patient standard of care costs.
Asche CV; Kim M; Feldman SR; Zografos P; Lu M
J Med Econ; 2017 Sep; 20(9):1000-1006. PubMed ID: 28581873
[TBL] [Abstract][Full Text] [Related]
38. Calcipotriol/betamethasone dipropionate: a review of its use in the treatment of psoriasis vulgaris of the trunk, limbs and scalp.
McCormack PL
Drugs; 2011 Apr; 71(6):709-30. PubMed ID: 21504248
[TBL] [Abstract][Full Text] [Related]
39. Patient-Reported Satisfaction With the Fixed Combination Calcipotriene/Betamethasone Dipropionate Foam for Plaque Psoriasis.
Gorelick J; Cantrell W; Kucera K; Veverka KA; Gooding K
J Drugs Dermatol; 2018 Aug; 17(8):880-884. PubMed ID: 30124727
[TBL] [Abstract][Full Text] [Related]
40. Early efficacy and safety data with fixed-dose combination calcipotriol/betamethasone dipropionate foam attributed to mechanism of absorption and steroid potency.
Tada Y; Iversen L; Koo J
J Eur Acad Dermatol Venereol; 2021 Feb; 35 Suppl 1(Suppl 1):5-9. PubMed ID: 33619779
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
